Autosomal dominant pseudohypoaldosteronism type 1: Mechanisms, evidence for neonatal lethality, and phenotypic expression in adults

Journal of the American Society of Nephrology

Volumn 17, Issue 5, 2006, Pages 1429-1436

  Geller, David S ^a   Zhang, Junhui ^a   Zennaro, Maria Christina ^b   Vallo Boado, Alberto ^c   Rodriguez Soriano, Juan ^c   Furu, Laszlo ^a   Haws, Robert ^d   Metzger, Daniel ^e   Botelho, Barbara ^f   Karaviti, Lefkothea ^g   Haqq, Andrea M ^h   Corey, Howard ⁱ   Janssens, Sandra ^j   Corvol, Pierre ^b   Lifton, Richard P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b l'alimentation et l'Environnement   (France)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d MARSHFIELD CLINIC   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MORRISTOWN MEMORIAL HOSPITAL   (United States)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; MINERALOCORTICOID RECEPTOR; RENIN;

ADULT; ADULT DISEASE; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT PSEUDOHYPOALDOSTERONISM TYPE 1; CARDIOVASCULAR DISEASE; DE NOVO MUTATION; FAMILY STUDY; FEMALE; GENE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HAPLOTYPE INSUFFICIENCY; HORMONE ACTION; HORMONE RESISTANCE; HUMAN; HYPERKALEMIA; HYPERRENINEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MR GENE; NEWBORN; NEWBORN MORTALITY; NONHUMAN; PHENOTYPE; PHENOTYPIC EXPRESSION; PRIORITY JOURNAL; PSEUDOHYPOALDOSTERONISM; RARE DISEASE; SALT INTAKE; SALT LOSING NEPHRITIS; SALT THERAPY; SODIUM BALANCE;

EID: 33646357245     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005111188     Document Type: Article

References (25)

1. Hanukoglu A: Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab 73: 936-944, 1991
2. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, Schild L, Lu Y, Shimkets RA, Nelson-Williams C, Rossier BC, Lifton RP: Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 12: 248-253, 1996
3. Strautnieks SS, Thompson RJ, Hanukoglu A, Dillon MJ, Hanukoglu I, Kuhnle U, Seckl J, Gardiner RM, Chung E: Localisation of pseudohypoaldosteronism genes to chromosome 16p12.2-13.11 and 12p13.1-pter by homozygosity mapping. Hum Mol Genet 5: 293-299, 1996
4. Hanukoglu A, Joy O, Steinitz M, Rosler A, Hanukoglu I: Pseudohypoaldosteronism due to renal and multisystem resistance to mineralocorticoids respond differently to carbenoxolone. J Steroid Biochem Mol Biol 60: 105-112, 1997
5. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, Lifton RP: Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 19: 279-281, 1998
6. Tajima T, Kitagawa H, Yokoya S, Tachibana K, Adachi M, Nakae J, Suwa S, Katoh S, Fujieda K: A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 85: 4690-4694, 2000
7. Viemann M, Peter M, Lopez-Siguero JP, Simic-Schleicher G, Sippell WG: Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: Identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds. J Clin Endocrinol Metab 86: 2056-2059, 2001
8. Sartorato P, Lapeyraque AL, Armanini D, Kuhnle U, Khaldi Y, Salomon R, Abadie V, Di Battista E, Naselli A, Racine A, Bosio M, Caprio M, Poulet-Young V, Chabrolle JP, Niaudet P, De Gennes C, Lecornec MH, Poisson E, Fusco AM, Loli P, Lombes M, Zennaro MC: Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 88: 2508-2517, 2003
9. Riepe FG, Krone N, Morlot M, Ludwig M, Sippell WG, Partsch CJ: Identification of a novel mutation in the human mineralocorticoid receptor gene in a german family with autosomal-dominant pseudohypoaldosteronism type 1: Further evidence for marked interindividual clinical heterogeneity. J Clin Endocrinol Metab 88: 1683-1686, 2003
10. Nystrom AM, Bondeson ML, Skanke N, Martensson J, Stromberg B, Gustafsson J, Anneren G: A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type I (PHA1). J Clin Endocrinol Metab 89: 227-231, 2004
11. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, et al.: Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79: 407-414, 1994
12. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, Torres VE, Somlo S: Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet 72: 691-703, 2003
13. Zennaro MC, Borensztein P, Jeunemaitre X, Armanini D, Soubrier F: No alteration in the primary structure of the mineralocorticoid receptor in a family with pseudohypoaldosteronism. J Clin Endocrinol Metab 79: 32-38, 1994
14. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, Lifton RP: Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289: 119-123, 2000
15. Hentze MW, Kulozik AE: A perfect message: RNA surveillance and nonsense-mediated decay. Cell 96: 307-310, 1999
16. Huey CL, Riepe FG, Sippell WG, Yu AS: Genetic heterogeneity in autosomal dominant pseudohypoaldosteronism type I: Exclusion of claudin-8 as a candidate gene. Am J Nephrol 24: 483-487, 2004
17. Sartorato P, Khaldi Y, Lapeyraque AL, Armanini D, Kuhnle U, Salomon R, Caprio M, Viengchareun S, Lombes M, Zennaro MC: Inactivating mutations of the mineralocorticoid receptor in type I pseudohypoaldosteronism. Mol Cell Endocrinol 217: 119-125, 2004
18. Karl M, Lamberts SW, Detera-Wadleigh SD, Encio IJ, Stratakis CA, Hurley DM, Accili D, Chrousos GP: Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 76: 683-689, 1993
19. Charmandari E, Kino T, Souvatzoglou E, Vottero A, Bhattacharyya N, Chrousos GP: Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: Molecular genotype, genetic transmission, and clinical phenotype. J Clin Endocrinol Metab 89: 1939-1949, 2004
20. Chatterjee VK, Nagaya T, Madison LD, Datta S, Rentoumis A, Jameson JL: Thyroid hormone resistance syndrome. Inhibition of normal receptor function by mutant thyroid hormone receptors. J Clin Invest 87: 1977-1984, 1991
21. Sakurai A, Miyamoto T, Refetoff S, DeGroot LJ: Dominant negative transcriptional regulation by a mutant thyroid hormone receptor-beta in a family with generalized resistance to thyroid hormone. Mol Endocrinol 4: 1988-1994, 1990
22. Chitayat D, Spirer Z, Ayalon D, Colander A: Pseudohypoaldosteronism in a female infant and her family: Diversity of clinical expression and mode of inheritance. Acta Paediatr Scand 74: 619-622, 1985
23. Brilla CG: Renin-angiotensin system mediated mechanisms: Cardioreparation and cardioprotection. Heart 84[Suppl 1]: i18-i19; discussion i50, 2000
24. Brilla CG: Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 47: 1-3, 2000
25. Losel R, Schultz A, Boldyreff B, Wehling M: Rapid effects of aldosterone on vascular cells: Clinical implications. Steroids 69: 575-578, 2004